Charleroi, Belgium
Charleroi, Belgium

Time filter

Source Type

News Article | April 17, 2017
Site: www.businesswire.com

TORONTO--(BUSINESS WIRE)--The Ontario Society of Medical Technologists (OSMT) is proud to celebrate National Medical Laboratory Week (NMLW) which runs April 16th - 22nd 2017. The OSMT has been representing laboratory professionals in Ontario since 1963. Every day in Ontario thousands of lab tests are performed by qualified and certified laboratory professionals. “Ontario laboratory professionals are an essential part of our healthcare team, but as they work behind the scenes, they are easily forgotten. This week is an opportunity to showcase our profession and appreciate the hard work that is done each and every day in Ontario laboratories,” says Michelle Hoad, OSMT Executive Director. During this week, across Ontario and the country, laboratory professionals participate in a variety of activities to help raise the profile of the profession and bring awareness to this essential health care team comprised of Medical Laboratory Technologists (MLTs) and Medial Laboratory Assistants/Technicians (MLA/Ts). “This year Ontario laboratory professionals will be seen wearing an OSMT pin, which has a picture of the Ontario flag. The flag represents pride in the profession and in our province. If you are getting blood work done, or walk by a lab in a hospital and see one of our team members, take a minute to say thank you for their hard work,” says OSMT President, Karim Bhaloo. The Ontario Society of Medical Technologists is the provincial organization for medical laboratory technologist and medical laboratory assistant/technicians. Incorporated in 1963, as the OSMT, it represents over 2500 lab professionals across Ontario and is growing.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Medical Laboratory Testing Services 2017 to 2022 - Latin America, Africa and Middle East Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Medical Laboratory Testing Services - 2016 to 2019 Latin America, Africa & Middle East Version" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. For more information about this report visit http://www.researchandmarkets.com/research/pw6nr5/medical


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Medical Laboratory Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends. Price & Volume Forecasts by Laboratory Department. 2017 to 2022 - Asia Pacific Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Medical Laboratory Testing Services - 2016 to 2019 Asia Pacific Version" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report. For more information about this report visit http://www.researchandmarkets.com/research/pxdgrh/medical


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Medical Laboratory Testing Services 2017 to 2022 - North America Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Medical Laboratory Testing Services - 2016 to 2019 North America Version" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. For more information about this report visit http://www.researchandmarkets.com/research/c3xkr8/medical


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Medical Laboratory Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends. Price & Volume Forecasts by Laboratory Department. 2017 to 2022 - Global Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Medical Laboratory Services Strategies, Trends and Forecasts 2015 to 2019 - Global Version provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. For more information about this report visit http://www.researchandmarkets.com/research/hm395j/medical


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Medical Laboratory Testing Services 2017 to 2022 - Europe Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Medical Laboratory Testing Services - 2016 to 2019 Europe Version" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report. 6. The Future of the Clinical Laboratory For more information about this report visit http://www.researchandmarkets.com/research/d4r96x/medical


News Article | March 3, 2017
Site: www.PR.com

Cyrex Laboratories Adds Unique Expertise with Two New Team Members Cyrex Laboratories continues to attract the best and brightest in immunology testing with additions of Dr. Mark Engelman and Michelle Clark. Phoenix, AZ, March 03, 2017 --( Dr. Engelman joins the Cyrex team as Clinical Consultant to provide his expert guidance on test result interpretation, clinical relevance of results, and possible treatment protocols. He will also speak on behalf of Cyrex at industry conferences and educational events as an authority on functional medicine. Dr. Engelman is a practicing physician specializing in internal medicine, with advanced degrees in stem cell and functional medicine. He is Founder and President of the Engelman Health Institute and has a 23-year tenure as the Director of St. Joseph's Medical Center emergency department in Phoenix, Arizona. Dr. Engelman also has the distinction of having been standby physician for two American presidential administrations, President of the Maricopa County American Heart Association, Chief Physician for the Arizona Boxing Commission; and is Founder and CEO of AmeriMed American Hospitals in Mexico. “The old paradigm for how we evaluate and respond to a patient’s health is on the way out,” said Dr. Engelman. “Medicine is becoming more personalized, and advances in immunology testing are a prime example of the shift toward a patient-specific, more holistic approach - and Cyrex Labs is at the forefront of this movement. I look forward to working with the Cyrex team to help patients learn more about how their immune systems respond to the environment and the foods they consume.” Michelle Clark has been tapped as Director of Sales to help execute Cyrex’s strategic growth plan. Clark’s 25-year focus on high-complexity laboratory testing will be an extraordinary asset in developing client relationships as she educates healthcare providers about the value of the Cyrex System. Clark is a business strategist, marketing expert, speaker and writer with extensive leadership and management experience. Prior to joining Cyrex, Clark was Director of Sales and Marketing at Alletess Medical Laboratory, where she was instrumental in the transformation of that company into an international allergy laboratory with sustainable and profitable growth. She is a Board Advisor for the International College of Integrative Medicine and a member of the American Academy of Environmental Medicine, where she serves on the Exhibitor Committee. Clark is also a current member of the American College of Nutrition. “Cyrex leads the industry in quality standards for laboratory testing. By sharing with healthcare providers the extra steps Cyrex takes to ensure the accuracy of its testing, I hope to help the business fully realize its growth potential,” said Clark. Physicians and other licensed healthcare professionals, as well as patients, interested in learning more about Cyrex and its unique approach to assessing immune reactivity and autoimmunity are encouraged to visit www.joincyrex.com for additional information. About Cyrex Laboratories Cyrex is a clinical immunology laboratory specializing in functional immunology and autoimmune reactivity. Cyrex offers multi-tissue antibody testing for the early detection and monitoring of today’s complex autoimmune conditions. Cyrex develops innovative testing arrays through continuous collaboration with leading experts in medical research and clinical practice. Cyrex technology is built on four pillars of excellence, including the antigen purification system, optimized antigen concentration, antigen-specific validation and parallel testing technology. Cyrex is a CLIA licensed laboratory based in Phoenix, Arizona and holds a Medical Device Establishment License in Canada. Phoenix, AZ, March 03, 2017 --( PR.com )-- Cyrex Laboratories, a leading clinical laboratory specializing in functional immunology and autoimmunity, continues to attract the highest caliber professionals to the organization. With the addition of Dr. Mark Engelman, M.D., FSCM, ABAARM, FAARM, and Michelle Clark, MBA, Cyrex further reinforces its team’s expertise in functional medicine and laboratory business development.Dr. Engelman joins the Cyrex team as Clinical Consultant to provide his expert guidance on test result interpretation, clinical relevance of results, and possible treatment protocols. He will also speak on behalf of Cyrex at industry conferences and educational events as an authority on functional medicine.Dr. Engelman is a practicing physician specializing in internal medicine, with advanced degrees in stem cell and functional medicine. He is Founder and President of the Engelman Health Institute and has a 23-year tenure as the Director of St. Joseph's Medical Center emergency department in Phoenix, Arizona. Dr. Engelman also has the distinction of having been standby physician for two American presidential administrations, President of the Maricopa County American Heart Association, Chief Physician for the Arizona Boxing Commission; and is Founder and CEO of AmeriMed American Hospitals in Mexico.“The old paradigm for how we evaluate and respond to a patient’s health is on the way out,” said Dr. Engelman. “Medicine is becoming more personalized, and advances in immunology testing are a prime example of the shift toward a patient-specific, more holistic approach - and Cyrex Labs is at the forefront of this movement. I look forward to working with the Cyrex team to help patients learn more about how their immune systems respond to the environment and the foods they consume.”Michelle Clark has been tapped as Director of Sales to help execute Cyrex’s strategic growth plan. Clark’s 25-year focus on high-complexity laboratory testing will be an extraordinary asset in developing client relationships as she educates healthcare providers about the value of the Cyrex System.Clark is a business strategist, marketing expert, speaker and writer with extensive leadership and management experience. Prior to joining Cyrex, Clark was Director of Sales and Marketing at Alletess Medical Laboratory, where she was instrumental in the transformation of that company into an international allergy laboratory with sustainable and profitable growth. She is a Board Advisor for the International College of Integrative Medicine and a member of the American Academy of Environmental Medicine, where she serves on the Exhibitor Committee. Clark is also a current member of the American College of Nutrition.“Cyrex leads the industry in quality standards for laboratory testing. By sharing with healthcare providers the extra steps Cyrex takes to ensure the accuracy of its testing, I hope to help the business fully realize its growth potential,” said Clark.Physicians and other licensed healthcare professionals, as well as patients, interested in learning more about Cyrex and its unique approach to assessing immune reactivity and autoimmunity are encouraged to visit www.joincyrex.com for additional information.About Cyrex LaboratoriesCyrex is a clinical immunology laboratory specializing in functional immunology and autoimmune reactivity. Cyrex offers multi-tissue antibody testing for the early detection and monitoring of today’s complex autoimmune conditions. Cyrex develops innovative testing arrays through continuous collaboration with leading experts in medical research and clinical practice. Cyrex technology is built on four pillars of excellence, including the antigen purification system, optimized antigen concentration, antigen-specific validation and parallel testing technology. Cyrex is a CLIA licensed laboratory based in Phoenix, Arizona and holds a Medical Device Establishment License in Canada. Click here to view the list of recent Press Releases from Cyrex Laboratories


BEVERLY HILLS, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- TOMI™ Environmental Solutions, Inc. (TOMI) (OTCQX:TOMZ), a global bacteria decontamination and infection prevention company, and its board of directors announced the formation and approval of  TOMI’s scientific advisory board. “We are honored William, Miguel and Helene – experts in intellectual property law, biosafety and infection prevention, respectively – have agreed to join our scientific advisory board,” stated Dr. Halden Shane, TOMI’s Chief Executive Officer. “We believe their support validates TOMI’s groundbreaking SteraMist™, and their guidance will help TOMI in "Innovating for a Safer World.” The team is charged with constructively challenging management to help develop strategy; ensuring the necessary resources are in place to enable us to achieve objectives in scientific research and development; and monitoring technological and regulatory trends that could impact our business as well as our performance against our goals. We believe their insight will be invaluable.” William M. Brown, PhD, MBA, JD William M. Brown, PhD, MBA, JD is a consultant and advisor to a series of biotech and life sciences companies. Dr. Brown is a seasoned attorney in intellectual property with deep experience in healthcare-related matters. He is licensed to practice law in several states and is a registered patent attorney. His consulting experience includes intellectual property portfolio management, clinical trial contracts, and patent/business development matters. He holds a PhD from the University of Southampton, England, an MBA from Fairleigh Dickinson University, and a JD from New York Law School. Dr. Brown conducted postdoctoral research at Harvard, Johnson & Johnson, NIH, and Memorial Sloan-Kettering Cancer Center. Miguel A. Grimaldo, MEng Miguel A. Grimaldo, MEng is an Assistant Professor for the Department of Pathology, Director of Institutional Biocontainment Resources at the University of Texas Medical Branch (UTMB) and the Director of the Biocontainment Engineering Division for the Galveston National Laboratory. His responsibilities include the review of all design, construction, commissioning and operation of High and Maximum containment laboratories as well as to ensure regulatory compliance and to conduct ongoing evaluation and recertification on all critical containment features, equipment and operations for Biosafety Level 3 (BSL‐3), Animal Biosafety Level 3 (ABSL3) and Biosafety Level 4 (BSL4) laboratory facilities at UTMB. He is also a member of the UTMB Institutional Biosafety Committee. He has served as Committee Member for development of the ANSI Z9.14‐2014 Standard ‐ Testing and Performance‐Verification Methodologies for Ventilation Systems for Biosafety Level 3 (BSL‐3) and Animal Biosafety Level 3 (ABSL‐3) facilities as well as for the 2016 Edition of the National Institute of Health (NIH) ‐ Design Requirements Manual (DRM) for Biomedical Laboratories and Animal Research Facilities. Miguel routinely serves as Biocontainment Advisor for containment laboratories nationally and internationally on design, construction and operations and also routinely contributes to a technical column in the American Biological Safety Association (ABSA) journal, Applied Biosafety entitled, “Containment Talk”. Mr. Grimaldo obtained his Masters of Engineering from the University of Louisville and Bachelor of Science degrees in Agricultural Engineering and Agricultural Economics from Texas A&M University. Dr. Helene Paxton, MS, MT(ASCP), PhD, CIC Dr. Helene Paxton, MS, MT(ASCP), PhD, CIC, is an Infection Preventionist, owner of Bio Guidance, LLC, adjunct biology professor at Rowan University and Director of Infection Prevention at Saint Francis Healthcare. She is Infection Control Certified (CIC), board certified as an International Medical Laboratory Scientist and holds a PhD in Epidemiology. Dr. Paxton has 40 plus years’ experience in medical devices and infectious disease consulting. Dr. Paxton obtained her PhD from Kennedy Western University and her MS from Bowling Green State University. Scientific Advisory Board Provisions and criteria have been set in the company's bylaws and scientific advisory board charter. TOMI’s scientific advisory board will always observe in the letter and spirit the duties, rights and role as a member of the company's board as stipulated in the relevant listing standards. About TOMI™ Environmental Solutions, Inc. TOMI™ Environmental Solutions, Inc. (OTCQX:TOMZ) is a global bacteria decontamination and infectious disease control company, providing eco-friendly environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier platform of Hydrogen Peroxide based product that uses Binary Ionization Technology® (BIT™) , a state of the art technology for the production of its Activated Ionized Hydrogen Peroxide mist represented by the TOMI™ SteraMist™ brand. TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences. TOMI also develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, The Restoration Industry Association, Indoor Air Quality Association, and The International Ozone Association. For additional product information, visit www.tomimist.com or contact us at info@tomimist.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.


News Article | February 21, 2017
Site: www.eurekalert.org

In both groups, recreational sun exposure, black hair-dye use, a history of hospitalization for infection, and having a first-degree relative with a blood cancer were associated with B-NHL. Each group had unique risk factors too. Non-Hodgkin lymphomas (NHL), tumors which may originate from B or T lymphocytes, account for approximately 3% of the worldwide cancer burden. Most epidemiological studies of NHL have been carried out in North American and European populations, with a few focusing on East Asian populations. Very few epidemiological studies have been conducted on B-cell non-Hodgkin lymphoma (B-NHL) in Middle Eastern populations. Since Israelis and Palestinians represent genetically and culturally diverse populations living in geographic proximity, research analyzing their risk factors can enrich our understanding of genes and environment in the causation of lymphoma. Despite sharing the same ecosystem, the populations differ in terms of lifestyle, health behaviors and medical systems. Yet both populations report high incidences of NHL, which represents the fifth most common malignancy in Israel and the eighth most common malignancy among West Bank Palestinians. (As of 2012, Israel also ranked first in the world in NHL incidence rates.) Now, Israeli and Palestinian researchers have conducted a large scale epidemiological study examining risk factors for B-NHL and its subtypes in these two populations. The team was led by Prof. Ora Paltiel, Director of the Hebrew University-Hadassah Braun School of Public Health and Community Medicine, in the Hebrew University's Faculty of Medicine, and a Senior Physician in Hadassah's Hematology Department. Recruiting from both the Palestinian Arab and Israeli Jewish populations, the researchers looked at medical history, environmental and lifestyle factors among 823 people with B-cell non-Hodgkin lymphoma (B-NHL) and 808 healthy controls. Using data from questionnaires, pathology review, serology and genotyping, they uncovered some risk factors common to both populations and other factors unique to each population. The data, reported in the peer-reviewed journal PLOS ONE, showed that in both populations, overall B-NHL was associated with recreational sun exposure, black hair-dye use, a history of hospitalization for infection, and having a first-degree relative with a blood cancer. An inverse association was noted with alcohol use. Some exposures, including smoking and greater-than-monthly indoor pesticide use, were associated with specific subtypes of B-NHL. The data also pointed to differences between the populations. Among Palestinian Arabs only, risk factors included gardening and a history of herpes, mononucleosis, rubella, or blood transfusion, while these factors were not identified in the Israeli Jewish population. In contrast, risk factors that applied to Israeli Jews only included growing fruits and vegetables, and self-reported autoimmune diseases. The researchers concluded that differences in the observed risk factors by ethnicity could reflect differences in lifestyle, medical systems, and reporting patterns, while variations by lymphoma subtypes infer specific causal factors for different types of the disease. These findings require further investigation as to their mechanisms. The fact that risk factors operate differently in different ethnic groups raises the possibility of gene-environment interactions, that is, that environmental exposures act differently in individuals of different genetic backgrounds. But this divergence may reflect differences in diet, cultural habits, socioeconomic, environmental and housing conditions, medical services, exposure to infections in early life or other factors. This study reflects a unique joint scientific effort involving Israeli and Palestinian investigators, and demonstrates the importance of cooperative research even in politically uncertain climates. Cancer epidemiology will be enriched through the broadening of analytic research to include under-studied populations from a variety of ethnicities and geographic regions. "Apart from the scientific contribution that this research provides in terms of understanding risk factors for NHL, the study entails an important research cooperation among many institutions. The study provided opportunities for training Palestinian and Israeli researchers, and will provide for intellectual interaction for years to come. The data collected will also provide a research platform for the future study of lymphoma. Epidemiologic research has the potential to improve and preserve human health, and it can also serve as a bridge to dialogue among nations," said Prof. Ora Paltiel, Director of the Hebrew University-Hadassah Braun School of Public Health and Community Medicine, and a Senior Physician in Hadassah's Hematology Department. Participating institutions in this research included: Braun School of Public Health and Community Medicine, and Depts. of Hematology and Pathology, Hadassah-Hebrew University Medical Center; Dept. of Medical Laboratory Sciences and Dept. of Community Medicine, Faculty of Medicine, Al Quds University; Cancer Care Center, Augusta Victoria Hospital; Beit Jalla Hospital; Department of Statistics, Hebrew University; Department of Primary Health Care, Palestinian Ministry of Health; Tisch Cancer Institute and Institute for Translational Epidemiology, Mount Sinai School of Medicine; Rambam Medical Center and Rappaport Faculty of Medicine, Technion; Chaim Sheba Medical Center and Meir Medical Center and Tel Aviv University.


News Article | March 3, 2017
Site: www.prweb.com

The parent company of leading healthcare staffing agency, Aureus Medical Group, has been named among the Best Places to Work in Omaha. C&A Industries, Inc., parent company to four staffing and recruitment firms has been recognized for the seventh time in nine years. C&A is included in the large company category organizations with more than 200 employees. Aureus Medical, headquartered in Omaha and the largest of C&A’s firms, specializes in travel nursing, travel therapy, and full time as well as travel opportunities in most all areas of allied health. The annual Best Places to Work in Omaha initiative, sponsored by the Greater Omaha Chamber of Commerce and Baird Holm, recognizes a select number of companies annually based on the results of surveys taken by the employees of participating organizations. Surveys measure employee engagement, satisfaction, morale, opportunities for professional growth, and workplace culture. “C&A is proud to be honored among a group of highly respected organizations,” said Scot Thompson, President and CEO of C&A Industries. “We believe that the catalyst to our success as a staffing provider and employer of choice on a local and national scale is the exceptional group of employees that comprise the C&A team. To be recognized from within, now for the seventh time, means a great deal to us.” Industry-leading training and professional development programs; its award-winning health and wellness program; and a companywide commitment to community involvement and philanthropy are, according to Thompson, key factors in maintaining C&A’s high levels of employee engagement and morale. He adds that year-round employee recognition programs and a focus on communication and idea sharing are also embraced by employees. “We are continually looking for ways to become an even better organization tomorrow than we are today and our employees play a significant role in this effort,” said Thompson. “They are at the heart of our positive and dynamic workplace, demonstrated through their commitment to excellence, spirit of teamwork and generosity, and by living our mission and values. We are fortunate to have the finest group of employees in Omaha and in our industry." C&A will be recognized along with other Best Places to Work in Omaha recipients during a luncheon in May 2017. Aureus Medical Group is a national leader in healthcare staffing specializing in the successful placement of Nursing, Advanced Practice, Cardiopulmonary, Diagnostic Imaging, Medical Laboratory, Neurodiagnostics, Radiation Oncology, and Rehabilitation Therapy professionals, as well as Physicians, in hospitals and medical facilities nationwide. With more than 30 years of experience, Aureus Medical offers a full range of staffing options, including national contract (travel), local contract, and direct hire. Aureus Medical is the largest affiliate of Omaha-based C&A Industries, a leading provider of human capital management solutions for more than 45 years.

Loading Medical Laboratory collaborators
Loading Medical Laboratory collaborators